Demonstrating your cell therapy’s superior safety and efficacy is vital for standing out in a competitive market and attracting investment. Integrating cutting-edge technologies and robust analytical methods is key to [….]
The Global Clinical Trials Connect 2024 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research. This multidisciplinary program involves broad participation of people [….]
Trialogics uses a variety of Samsung devices to create a customized, highly secure solution for clinical trial subjects, doctors, and site researchers.
Jonathan Mow appointed as CEO of Veralox Therapeutics
Developing new orphan therapies, increasing access to existing life-saving treatments, and lowering costs is a moral imperative. However, major challenges remain for the rare disease community to achieve these goals.
TYSONS CORNER, Va. (PRWEB) September 20, 2021 — Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Informatics, can significantly reduce the number of participants who drop out, thus improving the chances of success—for the trials and the therapeutic product itself.
Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority
LucasPye Bio, a Philadelphia biologics contract development and manufacturing organization, has formed a partnership with Africa-based genomics company IndyGeneUS AI aimed at advancing targeted therapeutics focused on health disparities.
Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders. Despite cardiovascular disease being the number-one cause of global death, Fraser said few companies are pouring their resources into addressing the disease, especially when compared to oncology research. Windtree’s lead clinical program istaroxime is a novel therapeutic aimed at heart failure, the number one reason for hospitalization in the United States.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.
